Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.
Liu GY, Ye YF, Jiang YF, Chen GJ, Xia WX, Huang YS, Gao TS, Liu YM, Hou YT, Li JF, Liu JH, Lu N, Chen CL, Ke LR, Liang H, Bei WX, Li WZ, Dong SH, Liu Q, Xie C, Yao HR, Xiang YQ
- DOI
- 10.1136/bmj-2023-077890
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/2e267a7a-6956-4c0e-a64c-a021f65465ac is authoritative.
How this rating was calculated
- StatisticsImpossible or misreported statistic ×4−4★
- IntegrityIntegrity concern−0.5★
- ClaimsOverstated claim−0.5★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- ReportingData & code availability partially met−0.25★
A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.
- No data or code availability links were detected to verify.
- 01Printed percentage does not match its own countdemonstrable
98% does not match the reported count 1/41
“1/41 (98%)”
- 02Printed percentage does not match its own countdemonstrable
92.5% does not match the reported count 3/40
“3/40 (92.5%)”
- 03Printed percentage does not match its own countdemonstrable
98% does not match the reported count 1/41
“1/41 (98%)”
Results - 04Printed percentage does not match its own countdemonstrable
92.5% does not match the reported count 3/40
“3/40 (92.5%)”
ResultsFind in source - 05Efficacy rests on an unvalidated surrogate endpoint
The primary endpoint is progression-free survival (PFS), a surrogate for overall survival. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking PFS to overall survival in this specific disease context. The authors acknowledge that overall survival data are immature and that the correlation between PFS and OS is uncertain, especially with subsequent treatments.
“The overall survival data were still immature for both cohorts at the time of analysis.”
- 06Treatment effect not shown to be clinically meaningful
The primary effect is a median PFS improvement from 7.7 to 11.3 months (HR 0.43). While statistically significant, the clinical meaningfulness is not anchored to a minimal clinically important difference or a validated threshold. The authors claim a 'substantial extension' but do not provide a benchmark for what constitutes a clinically meaningful PFS gain in this setting.
“The nab-TPC regimen showed a substantial extension in progression-free survival compared with the conventional gemcitabine plus cisplatin chemotherapy regimen.”
1 further finding of this severity or below — every one is in the sections below, filed under its error type.
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted phase 3 randomised controlled trial with rigorous design, clear ethical approvals, and appropriate statistical methods. The main weaknesses are the vague data availability statement, lack of explicit reporting guideline adherence, and a slightly overstated conclusion given the interim nature of the analysis.
Both reviewers agreed on all dimensions and study type (interventional). The statistics verification component could only recompute a subset of tests (8 of 12 reported with sufficient detail); the remaining 4 were threshold-only or resampling-based and could not be machine-verified, so no claim of overall statistical correctness is made. The citation check found no retracted or unresolved references.
Numerical inconsistencies
2 findings · worst criticalValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
- Internal contradictions in the reported numbersAssessed
Recomputed 8 tests: 8 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 7 via agent-written checks. 4 reported summary statistics mathematically impossible for the stated N (PERCENT).
- PERCENT98% does not match the reported count 1/41
“1/41 (98%)”
- PERCENT92.5% does not match the reported count 3/40
“3/40 (92.5%)”
- PERCENT98% does not match the reported count 1/41
“1/41 (98%)”
Results - PERCENT92.5% does not match the reported count 3/40
“3/40 (92.5%)”
ResultsFind in source
- CONSISTENTreported p = .002 · recomputed p = .002Recomputed hazard ratio 0.43 (95% CI 0.25–0.73), reported p=0.002
“hazard ratio 0.43, 95% confidence interval 0.25 to 0.73; P=0.002”
Taken as given: 0.25–0.73 is a two-sided 95% confidence interval for the hazard ratio of 0.43, not a range, an IQR, or a different interval level; the hazard ratio is a RATIO measure, so the interval is symmetric on the log scale; p=0.002 is the p for THIS estimate, not for another comparison in the same sentenceMethod: back the two-tailed p out of the log-scale CI width and compare it against the printed pHow we recomputed it: pCI(0.43, 0.25, 0.73, 1) - CONSISTENTreported p = .002 · recomputed p = .002Reviewer 1P-value for hazard ratio of progression-free survival (interim analysis)
“The hazard ratio was 0.43 (95% confidence interval 0.25 to 0.73; P=0.002).”
Taken as given: The hazard ratio is 0.43 with 95% CI 0.25 to 0.73.; The CI is two-sided at 95%.; The p-value is two-sided.Method: Recomputed p-value from the hazard ratio and its 95% confidence interval using the normal approximation for the log hazard ratio.How we recomputed it: pCI(0.43, 0.25, 0.73, 1) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1P-value for hazard ratio of progression-free survival (updated analysis)
“The hazard ratio was 0.39 (0.24 to 0.65; P<0.001) (supplementary figure D).”
Taken as given: The hazard ratio is 0.39 with 95% CI 0.24 to 0.65.; The CI is two-sided at 95%.; The p-value is two-sided.Method: Recomputed p-value from the hazard ratio and its 95% confidence interval using the normal approximation for the log hazard ratio.How we recomputed it: pCI(0.39, 0.24, 0.65, 1) - CONSISTENTreported p = .009 · recomputed p = .009Reviewers 1, 2P-value for hazard ratio of duration of response
“with a hazard ratio of 0.42 (0.22 to 0.81; P=0.009)”
Taken as given: The hazard ratio is 0.42 with 95% CI 0.22 to 0.81.; The CI is two-sided at 95%.; The p-value is two-sided.Method: Recomputed p-value from the hazard ratio and its 95% confidence interval using the normal approximation for the log hazard ratio.How we recomputed it: pCI(0.42, 0.22, 0.81, 1) - CONSISTENTreported p = .050 · recomputed p = .039Reviewers 1, 2P-value for objective response rate comparison (interim analysis)
“The objective response rate in the nab-TPC cohort was 83% (34/41) versus 63% (25/40) in the gemcitabine and cisplatin cohort (P=0.05)”
Taken as given: The numbers are 34 responders out of 41 in nab-TPC, and 25 responders out of 40 in GP.; The test used is Pearson's chi-square test (as stated in methods).; The p-value is two-sided.Method: Recomputed two-sided p-value using Pearson's chi-square test on the 2x2 table.How we recomputed it: pChi2x2(34, 7, 25, 15) - CONSISTENTreported p = .020 · recomputed p = .015Reviewer 1P-value for leukopenia grade 3-4 comparison
“leukopenia (4/41 (10%) v 13/40 (33%); P=0.02)”
Taken as given: The numbers are 4 events out of 41 in nab-TPC, and 13 events out of 40 in GP.; The test used is Fisher's exact test (as stated in methods).; The p-value is two-sided.Method: Recomputed two-sided p-value using Fisher's exact test on the 2x2 table.How we recomputed it: pFisher2x2(4, 37, 13, 27, 0) - CONSISTENTreported p = .010 · recomputed p = .013Reviewer 1P-value for neutropenia grade 3-4 comparison
“neutropenia (6/41 (15%) v 16/40 (40%); P=0.01)”
Taken as given: The numbers are 6 events out of 41 in nab-TPC, and 16 events out of 40 in GP.; The test used is Fisher's exact test (as stated in methods).; The p-value is two-sided.Method: Recomputed two-sided p-value using Fisher's exact test on the 2x2 table.How we recomputed it: pFisher2x2(6, 35, 16, 24, 0) - CONSISTENTreported p = .010 · recomputed p = .014Reviewer 1P-value for anaemia grade 3-4 comparison
“anaemia (1/41 (2%) v 8/40 (20%); P=0.01)”
Taken as given: The numbers are 1 event out of 41 in nab-TPC, and 8 events out of 40 in GP.; The test used is Fisher's exact test (as stated in methods).; The p-value is two-sided.Method: Recomputed two-sided p-value using Fisher's exact test on the 2x2 table.How we recomputed it: pFisher2x2(1, 40, 8, 32, 0)
- lowinternal contradictionThe abstract reports objective response rate as 83% (34/41) vs 63% (25/40) with P=0.05, while the discussion states 82.9% vs 62.5% with P=0.05; the percentages are consistent but the discussion uses more decimal places.
“the nab-TPC regimen achieved a significant 20% improvement in objective response rate compared with the gemcitabine plus cisplatin group during the initial phase of induction chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (82.9% v 62.5%; P=0.05).”
DiscussionFind in source
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions overstated beyond the evidenceAssessed
5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).
- overstatedReviewers 1, 2Nab-TPC should be considered the standard first line treatment for recurrent or metastatic nasopharyngeal carcinoma.The claim is strong given the significant PFS benefit, but the trial was terminated early at interim analysis, overall survival data are immature, and the sample size is small (81 patients). The authors themselves note longer follow-up is needed.Evidence: The trial met its primary endpoint, but OS data are immature and the study is small.
“Nab-TPC should be considered the standard first line treatment for recurrent or metastatic nasopharyngeal carcinoma.”
ConclusionFind in source - supportedReviewers 1, 2The nab-TPC regimen showed superior antitumoural efficacy compared with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma.The primary endpoint of progression-free survival was significantly improved with HR 0.43 (95% CI 0.25-0.73, P=0.002), and objective response rate was higher (83% vs 63%, P=0.05).Evidence: Interim analysis results: median PFS 11.3 vs 7.7 months, HR 0.43, P=0.002; ORR 83% vs 63%, P=0.05.
“The nab-TPC regimen showed a superior antitumoural efficacy and favourable safety profile compared with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma.”
AbstractFind in source - supportedReviewers 1, 2The nab-TPC regimen has a favourable safety profile compared with gemcitabine and cisplatin.Grade 3-4 haematological adverse events were significantly lower in the nab-TPC group, and no treatment-related deaths occurred.Evidence: Leukopenia 10% vs 33% (P=0.02), neutropenia 15% vs 40% (P=0.01), anaemia 2% vs 20% (P=0.01); no treatment-related deaths.
“Treatment related grade 3 or 4 adverse events, including leukopenia (4/41 (10%) v 13/40 (33%); P=0.02), neutropenia (6/41 (15%) v 16/40 (40%); P=0.01), and anaemia (1/41 (2%) v 8/40 (20%); P=0.01), were higher in the gemcitabine and cisplatin cohort than in the nab-TPC cohort.”
AbstractFind in source - supportedReviewer 1The nab-TPC regimen offers a statistically significant enhancement in progression-free survival compared with the current standard-of-care gemcitabine plus cisplatin regimen.The primary endpoint was met with a significant HR of 0.43 (P=0.002) in the interim analysis.Evidence: HR 0.43, 95% CI 0.25-0.73, P=0.002.
“In summary, our findings show, for the first time, that the nab-TPC regimen offers a statistically significant enhancement in progression-free survival compared with the current standard-of-care gemcitabine plus cisplatin regimen in recurrent or metastatic nasopharyngeal carcinoma as a first line treatment.”
DiscussionFind in source - supportedReviewer 2The nab-TPC regimen significantly improved objective response rate compared with gemcitabine and cisplatin.The objective response rate was 83% vs 63% with P=0.05, which is borderline but statistically significant as reported.Evidence: ORR 34/41 (83%) vs 25/40 (63%), P=0.05.
“The objective response rate in the nab-TPC cohort was 83% (34/41) versus 63% (25/40) in the gemcitabine and cisplatin cohort (P=0.05)”
AbstractFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary endpoint is progression-free survival (PFS), a surrogate for overall survival. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking PFS to overall survival in this specific disease context. The authors acknowledge that overall survival data are immature and that the correlation between PFS and OS is uncertain, especially with subsequent treatments.
“The overall survival data were still immature for both cohorts at the time of analysis.”
- INADEQUATEEffect sizeThe primary effect is a median PFS improvement from 7.7 to 11.3 months (HR 0.43). While statistically significant, the clinical meaningfulness is not anchored to a minimal clinically important difference or a validated threshold. The authors claim a 'substantial extension' but do not provide a benchmark for what constitutes a clinically meaningful PFS gain in this setting.
“The nab-TPC regimen showed a substantial extension in progression-free survival compared with the conventional gemcitabine plus cisplatin chemotherapy regimen.”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
The introduction cites the landmark phase 3 trial establishing gemcitabine plus cisplatin as standard, notes the limited median progression-free survival of 7.0-7.7 months, and references prior work on capecitabine maintenance and nab-paclitaxel. The rationale for the study follows logically from these findings. Limitations of prior research are implicitly addressed by the design of a new regimen to improve efficacy.
“A phase 3 study has shown that gemcitabine plus cisplatin prolongs progression-free survival and overall survival in comparison with 5-fluorouracil plus cisplatin, which led to the establishment of gemcitabine plus cisplatin as the front line regimen for recurrent or metastatic nasopharyngeal carcinoma.”
“However, median progression-free survival derived from the gemcitabine plus cisplatin regimen remains limited, ranging from 7.0 to 7.7 months according to data from several prospective clinical studies.”
“We designed this phase 3, open label, randomised trial to evaluate the efficacy and safety of nab-paclitaxel, cisplatin, and capecitabine (nab-TPC) as first line treatment for recurrent or metastatic nasopharyngeal carcinoma compared with a gemcitabine plus cisplatin regimen.”
“A phase 3 study has shown that gemcitabine plus cisplatin prolongs progression-free survival and overall survival in comparison with 5-fluorouracil plus cisplatin, which led to the establishment of gemcitabine plus cisplatin as the front line regimen for recurrent or metastatic nasopharyngeal carcinoma.”
“However, median progression-free survival derived from the gemcitabine plus cisplatin regimen remains limited, ranging from 7.0 to 7.7 months according to data from several prospective clinical studies.”
“Hence, innovative strategies are needed to enhance clinical benefits while maintaining an acceptable toxicity profile.”
Randomization used a computer-generated permuted block design with opaque sealed envelopes. The trial was open-label but the independent review committee was masked. A sample size calculation was provided (134 patients, 80% power, HR 0.42). Inclusion/exclusion criteria were specified. The analysis population (ITT) and safety population were defined. Outlier handling is not explicitly described but the analysis population is pre-specified.
“A computer generated random number code was provided for randomisation of enrolled patients at the Sun Yat-sen University Cancer Center. Random distribution sequences were generated using a permuted block of flexible size (2, 4, 6, or 8), with no stratification factors.”
“The therapy assignment was not masked to investigators, patients, and other treating oncologists, but the central evaluation of the imaging data by an independent review committee was done in a masked manner.”
“We calculated that we would need to randomise approximately 134 patients (67 patients per group), providing 80% power to detect the underlying hazard ratio of 0.42 for the primary analysis of progression-free at a two sided α level of 5% with one interim analysis.”
“A computer generated random number code was provided for randomisation of enrolled patients at the Sun Yat-sen University Cancer Center. Random distribution sequences were generated using a permuted block of flexible size (2, 4, 6, or 8), with no stratification factors.”
“The therapy assignment was not masked to investigators, patients, and other treating oncologists, but the central evaluation of the imaging data by an independent review committee was done in a masked manner.”
“We calculated that we would need to randomise approximately 134 patients (67 patients per group), providing 80% power to detect the underlying hazard ratio of 0.42 for the primary analysis of progression-free at a two sided α level of 5% with one interim analysis.”
The study reports age, sex, ECOG performance status, histology, smoking status, disease status, number of metastatic organs, and baseline EBV DNA. These are adequate for a human trial. Sex is reported for both groups, and since both sexes are enrolled, sex_justified is not applicable.
“Male | 34 (83) | 30 (75) | 64 (79)”
“Median (IQR) age, years | 47 (36-57) | 48 (36-56) | 48 (36-57)”
“The median age was 48 (interquartile range 36-57) years, and 79% of patients were male.”
“Baseline demographics and disease characteristics were balanced between the treatment groups ().”
The study was approved by the Chinese Ethics Committee of Registering Clinical Trials (ChiECRCT20190198) and conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. All participants provided written informed consent.
“This study was approved the Chinese Ethics Committee of Registering Clinical Trials (ChiECRCT20190198) and was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.”
“All participants provided written informed consent.”
“This study was approved the Chinese Ethics Committee of Registering Clinical Trials (ChiECRCT20190198) and was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.”
“All participants provided written informed consent.”
The trial uses nab-paclitaxel, cisplatin, capecitabine, and gemcitabine, all named with doses and schedules. This satisfies the reagents_identified criterion for a drug trial. Statistical software (R and SPSS) is identified. No antibodies, cell lines, or organisms are used, so those criteria are not applicable.
“Patients assigned to the nab-TPC cohort received nab-paclitaxel (200 mg/m 2 ) on day 1, cisplatin (60 mg/m 2 ) on day 1, and capecitabine (1000 mg/m 2 twice daily) on days 1-14 of each three week cycle for up to six cycles, followed by capecitabine maintenance for a maximum of two years.”
“We used R software (version 4.0.5) and SPSS (version 24.0) for statistical analyses.”
“Patients assigned to the nab-TPC cohort received nab-paclitaxel (200 mg/m 2 ) on day 1, cisplatin (60 mg/m 2 ) on day 1, and capecitabine (1000 mg/m 2 twice daily) on days 1-14 of each three week cycle for up to six cycles, followed by capecitabine maintenance for a maximum of two years.”
“We used R software (version 4.0.5) and SPSS (version 24.0) for statistical analyses.”
The paper names the tests used (Mann-Whitney, chi-square, Fisher's exact, Kaplan-Meier, log-rank, Cox proportional hazards). It reports exact p-values (e.g., P=0.002) and effect sizes with 95% CIs. The proportional hazards assumption was checked and found unmet, which is acknowledged. Statistical software is identified. Data presentation includes Kaplan-Meier curves and tables with per-group n. Mathematical plausibility checks were not possible for most statistics due to lack of raw data, but no obvious errors were found.
“We presented continuous variables as medians with interquartile ranges and compared them by using the Mann-Whitney test. We assessed categorical variables by using either the χ 2 test or Fisher’s exact test for comparison.”
“The hazard ratio was 0.43 (95% confidence interval 0.25 to 0.73; P=0.002).”
“The proportional hazards assumption for progression-free survival was unmet (supplementary figure A).”
“We presented continuous variables as medians with interquartile ranges and compared them by using the Mann-Whitney test. We assessed categorical variables by using either the χ 2 test or Fisher’s exact test for comparison.”
“We verified the assumption of proportional hazards by examining the Schoenfeld residuals.”
“The hazard ratio was 0.43 (95% confidence interval 0.25 to 0.73; P=0.002).”
The data availability statement says the raw database will be deposited on the Research Data Deposit public platform and requests can be made through the corresponding author, but it does not specify the access conditions or timeframe. The statistical code is mentioned as an online supplement, but no repository or permanent identifier is given. Therefore, data_availability_statement is reported_but_inadequate, and code_sharing is reported_but_inadequate.
“The codes used for analysis are provided as an online supplement.”
“The codes used for analysis are provided as an online supplement.”
The trial is registered (ChiCTR1900027112). Methods are detailed enough for replication. Limitations are explicitly discussed. Conclusions are proportional to the evidence, with appropriate caveats about overall survival. Funding sources and competing interests are declared. No reporting guideline is explicitly mentioned, but the paper follows CONSORT-like structure.
“Trial registration Chinese Clinical Trial Registry ChiCTR1900027112.”
“This trial has some inevitable limitations. Firstly, as all participants were sourced from endemic areas in China where non-keratinising nasopharyngeal carcinoma comprises more than 95% of cases, whether the findings can be extrapolated to non-endemic regions without further validation remains uncertain.”
“Funding: This study was supported by the Guangdong Basic and Applied Basic Research Foundation (grant No 2021B1515120013), the National Natural Science Foundation of China (Nos 82203755, 62220106006, and 82303338), the China Postdoctoral Science Foundation (CPSF) (2023T160749 and 2023T160146), and the Postdoctoral Fellowship Programme of CPSF (GZB20230179).”
“Trial registration Chinese Clinical Trial Registry ChiCTR1900027112.”
“This trial has some inevitable limitations. Firstly, as all participants were sourced from endemic areas in China where non-keratinising nasopharyngeal carcinoma comprises more than 95% of cases, whether the findings can be extrapolated to non-endemic regions without further validation remains uncertain.”
“Funding: This study was supported by the Guangdong Basic and Applied Basic Research Foundation (grant No 2021B1515120013), the National Natural Science Foundation of China (Nos 82203755, 62220106006, and 82303338), the China Postdoctoral Science Foundation (CPSF) (2023T160749 and 2023T160146), and the Postdoctoral Fellowship Programme of CPSF (GZB20230179).”
Registered (1 ID: Chinese Clinical Trial Registry). No reporting guideline cited.
Broken references and links
None found · partly checkedReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.
Checked 21 references by DOI: 21 verified.
Every extracted reference resolved against Crossref/OpenAlex with no retraction flags.
Copyediting
6 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 6 minor suggestions below.
6 copyedit issues flagged: mostly consistency, typo, grammar.
- MINORtypoAbstract, Results“nab-paclitaxel (200 g/m 2 on day 1)”→ Change 'g/m 2' to 'mg/m 2'.The dose unit is missing the 'm' for milligram.
- MINORgrammarMethods, Procedures“We used the National Cancer Institute Common Terminology Criteria, version 4.0, to evaluated adverse events”→ Change 'to evaluated' to 'to evaluate'.Incorrect verb form after 'to'.
- MINORconsistencyResults, Efficacy“1/41 (98%) v 3/40 (92.5%)”→ Correct the disease control rate numbers; likely should be 40/41 (98%) and 37/40 (92.5%).The numerator appears to be missing a digit; the percentage suggests 40/41 and 37/40.
- MINORclarityDiscussion, Comparison with other studies“the nab-TPC regimen achieved a significant 20% improvement in objective response rate compared with the gemcitabine plus cisplatin group during the initial phase of induction chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (82.9% v 62.5%; P=0.05).”→ Clarify that the 20% improvement is an absolute difference in percentage points, not a relative improvement.The phrase '20% improvement' could be misinterpreted.
- MINORconsistencyResults, Efficacy“1/41 (98%) v 3/40 (92.5%)”→ Correct the disease control rate percentages; likely 40/41 (98%) and 37/40 (92.5%).The numerator appears to be missing a digit.
- MINORconsistencyDiscussion, Comparison with other studies“82.9% v 62.5%”→ Ensure consistency with the 83% and 63% reported in the abstract and results.Percentages differ slightly; may be due to rounding.
The published work is robust and generally trustworthy, but an informed reader should weigh the interim-analysis context, the immature overall survival data, and the slightly overstated conclusion. The vague data/code availability and minor copyedit errors (e.g., a likely typo in the disease control rate) are worth noting but do not undermine the core findings.
- 1.CRITICALstatisticsCorrect or explain the statistically impossible value: PERCENT: 98% does not match the reported count 1/41Demonstrable critical failure — blocks the verdict from passing.
- 2.CRITICALstatisticsCorrect or explain the statistically impossible value: PERCENT: 92.5% does not match the reported count 3/40Demonstrable critical failure — blocks the verdict from passing.
- 3.HIGHreportingIn the Conclusion, temper the claim that nab-TPC 'should be considered the standard first line treatment' to reflect that the trial was stopped at interim analysis, overall survival data are immature, and the sample size is small (81 patients).The claim audit and Reviewer 2 both flagged this as overstated; over-claiming is a common reviewer objection and could undermine reader trust.
- 4.HIGHdata codeIn the Data availability statement, specify the access conditions and timeframe for requesting the raw database from the Research Data Deposit platform, and provide a persistent identifier (DOI or accession number) once available.The current statement is vague about how and when data can be accessed, which limits reproducibility.
- 5.HIGHdata codeDeposit the statistical code in a public repository (e.g., Zenodo, GitHub) with a DOI and link it in the Methods/Statistical analysis section.The code is only mentioned as an online supplement without a stable link, making it difficult for readers to access and verify the analyses.
- 6.MEDIUMreportingIn the Methods, explicitly state adherence to the CONSORT reporting guideline for randomised trials and provide the CONSORT checklist as a supplement.Reporting guidelines improve transparency and are expected for clinical trials; the paper currently does not mention one.
- 7.MEDIUMstatisticsIn the Methods/Statistical analysis, clarify the handling of missing data and any imputation methods used for the primary analysis.Missing data handling is not described, which is a common reviewer concern for trial analyses.
- 8.MEDIUMstatisticsIn the Results, report the number of patients with missing data for each endpoint and how they were handled in the analysis.Transparency about missing data is essential for assessing the robustness of the results.
- 9.MEDIUMreportingIn the Discussion, expand on the implications of the unmet proportional hazards assumption for the interpretation of the hazard ratio.The paper notes the assumption was unmet but does not discuss what this means for the validity of the HR estimate.
- 10.MEDIUMreportingIn the Methods, specify the exact version of the trial protocol and where it can be accessed (e.g., supplementary material).Providing the protocol version and location enhances transparency and reproducibility.
- 11.MEDIUMdata codeIn the Data availability statement, clarify whether the statistical code is included in the online supplement or available separately.The current statement is ambiguous about the code's availability.
- 12.MEDIUMreportingIn the Methods, state whether any data monitoring committee charter or statistical analysis plan is publicly available.Public availability of these documents strengthens the trial's transparency.
- 13.MEDIUMcopyeditIn the Abstract, Results, correct the dose unit 'g/m 2' to 'mg/m 2' for nab-paclitaxel.The unit is missing the 'm' for milligram, which is a factual error that could mislead readers.
- 14.MEDIUMcopyeditIn the Methods, Procedures, change 'to evaluated' to 'to evaluate'.Incorrect verb form after 'to' is a grammatical error that should be fixed.
- 15.MEDIUMcopyeditIn the Results, Efficacy, correct the disease control rate numbers from '1/41 (98%) v 3/40 (92.5%)' to '40/41 (98%) v 37/40 (92.5%)'.The numerator appears to be missing a digit; the percentages indicate the correct values.
- 16.LOWcopyeditIn the Discussion, Comparison with other studies, clarify that the '20% improvement' in objective response rate is an absolute difference in percentage points, not a relative improvement.The phrase could be misinterpreted as a relative improvement, which would be misleading.
- 17.LOWcopyeditIn the Discussion, ensure consistency between the percentages reported (82.9% v 62.5%) and those in the abstract/results (83% v 63%).Minor rounding differences could confuse readers; standardize the decimal places.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.